An Act Concerning The Department Of Social Services.
SB 1474 makes several changes to the Department of Social Services’ Medicaid and HUSKY B coverage rules. First, it expands coverage for obesity-related treatment by requiring the Commissioner of Social Services to provide medical assistance for bariatric surgery and related services for Medicaid and HUSKY B beneficiaries with severe obesity, and to cover medical services for beneficiaries with a BMI above 35, including FDA-approved weight loss drugs. The bill also requires continued coverage of weight loss drugs even if a patient’s BMI falls below 35, so long as a licensed physician certifies that stopping the medication would likely cause the BMI to rise above that threshold again.
The bill defines key terms such as obesity, severe obesity, bariatric surgery, medical services, and weight loss drugs, and authorizes the commissioner to amend the Medicaid state plan and the Children’s Health Insurance Program state plan as needed to implement these changes. In addition, it adds a new requirement that any Medicaid state plan amendment not otherwise subject to legislative approval must be submitted to the Human Services Committee, which must vote on it within 30 days before the commissioner may send it to federal officials for approval.
A separate provision addresses opioid prescribing under Medicaid. It requires prescribing practitioners who seek Medicaid reimbursement for prescribing opioid drugs to complete training in effective pain management, including nonopioid alternatives and the pros and cons of those alternatives in light of a patient’s risk of substance misuse. The commissioner is also authorized to adopt regulations to carry out this requirement.
Overall, the bill would expand Medicaid and HUSKY B benefits for obesity treatment while also adding oversight of Medicaid state plan amendments and imposing a new training condition tied to opioid prescribing reimbursement. It would affect the Department of Social Services, Medicaid providers, HUSKY B beneficiaries, and practitioners prescribing opioids to Medicaid recipients, and it would likely require administrative and possibly federal plan changes to implement.
The bill appears to have received generally favorable committee support, passing the Human Services Committee on a 16-6 vote. The available record does not include transcript discussion, but the structure of the bill suggests support for broader access to obesity treatment and stronger oversight of Medicaid policy changes, alongside some likely concern about cost, administrative burden, and the added requirements on prescribers and DSS.
The bill amends Connecticut’s Medicaid-related statutes to require coverage for bariatric surgery, obesity-related medical services, and GLP-1 weight loss drugs for eligible Medicaid and HUSKY B beneficiaries, and it creates a continuing-coverage rule for certain patients whose BMI improves on medication. It also adds a new legislative review step for Medicaid state plan amendments not otherwise subject to approval, and it imposes a Medicaid reimbursement condition requiring opioid-prescribing practitioners to complete pain-management training. These changes primarily affect DSS, Medicaid and HUSKY B enrollees, prescribing practitioners, and the Human Services Committee.
The available voting history indicates the bill was generally well received in committee, with a 16-6 Joint Favorable vote. That suggests a majority viewed the bill as a positive step toward expanding access to obesity treatment and improving oversight and prescribing practices. The six dissenting votes indicate meaningful reservations, likely centered on fiscal impact, administrative complexity, and the scope of new coverage and training mandates.
The main points of contention appear to be the expansion of state-funded coverage for bariatric surgery and GLP-1 weight loss drugs, the requirement to continue coverage even after BMI drops below 35, and the new committee approval process for Medicaid state plan amendments. Opponents may be concerned about program costs, utilization growth, and added administrative delays, while supporters likely emphasize access to medically necessary obesity treatment and greater legislative oversight of Medicaid policy changes. The opioid-training requirement may also draw concern from providers over added compliance obligations, though it is framed as a condition for Medicaid reimbursement rather than a general licensure mandate.